Xingqi Pharmaceutical released its first-quarter performance, with a net profit attributable to the parent company of 146 million yuan, an increase of 319.86%
I'm LongbridgeAI, I can summarize articles.According to the Zhitong Finance APP, Xingqi Pharmaceutical released its first-quarter report for 2025, with operating revenue of 536 million yuan, a year-on-year increase of 53.24%. The net profit attributable to shareholders of the listed company was 146 million yuan, a year-on-year increase of 319.86%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 136 million yuan, a year-on-year increase of 285.96%. The basic earnings per share were 0.83 yuan
According to the Zhitong Finance APP, Xingqi Pharmaceutical (300573.SZ) released its first quarter report for 2025, with operating revenue of 536 million yuan, a year-on-year increase of 53.24%. The net profit attributable to shareholders of the listed company was 146 million yuan, a year-on-year increase of 319.86%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 136 million yuan, a year-on-year increase of 285.96%. The basic earnings per share were 0.83 yuan